Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β-cell function and the achievement of the HbA1c target 1 year after initiation

Ryota Usui; Yui Sakuramachi; Yusuke Seino; Kenta Murotani; Hitoshi Kuwata; Hisato Tatsuoka; Yoshiyuki Hamamoto; Takeshi Kurose; Yutaka Seino; Daisuke Yabe

doi:10.1111/jdi.12858

Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β-cell function and the achievement of the HbA1c target 1 year after initiation

Ryota Usui
, Yui Sakuramachi
, Yusuke Seino
, Kenta Murotani
, Hitoshi Kuwata
, Hisato Tatsuoka
, Yoshiyuki Hamamoto
, Takeshi Kurose
, Yutaka Seino
, Daisuke Yabe

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	981-983
Number of pages	3
Journal	Journal of Diabetes Investigation
Volume	9
Issue number	4
DOIs	https://doi.org/10.1111/jdi.12858
Publication status	Published - 07-2018
Externally published	Yes

All Science Journal Classification (ASJC) codes

Internal Medicine
Endocrinology, Diabetes and Metabolism

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jdi.12858

Cite this

Usui, R., Sakuramachi, Y., Seino, Y., Murotani, K., Kuwata, H., Tatsuoka, H., Hamamoto, Y., Kurose, T., Seino, Y., & Yabe, D. (2018). Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β-cell function and the achievement of the HbA1c target 1 year after initiation. Journal of Diabetes Investigation, 9(4), 981-983. https://doi.org/10.1111/jdi.12858

Usui, Ryota ; Sakuramachi, Yui ; Seino, Yusuke et al. / Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes : The association between remaining β-cell function and the achievement of the HbA1c target 1 year after initiation. In: Journal of Diabetes Investigation. 2018 ; Vol. 9, No. 4. pp. 981-983.

@article{70ceeceeb2c740e4ac4030c634dd3e81,

title = "Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β-cell function and the achievement of the HbA1c target 1 year after initiation",

author = "Ryota Usui and Yui Sakuramachi and Yusuke Seino and Kenta Murotani and Hitoshi Kuwata and Hisato Tatsuoka and Yoshiyuki Hamamoto and Takeshi Kurose and Yutaka Seino and Daisuke Yabe",

note = "Funding Information: Daisuke Yabe received consulting or speaker fees from MSD K.K., Novo Nor disk Pharma Ltd., Takeda Pharmaceutical Company Limited and Taisho Toyama Pharmaceutical Co. Ltd. Daisuke Yabe also received clinically commissioned/ joint research grants from Nippon Boeh ringer Ingelheim Co., Ltd., Eli Lilly and Company, Taisho Toyama Pharmaceutical Co. Ltd., MSD K.K., Ono Pharmaceutical Co. Ltd., Novo Nordisk Pharma Ltd., Arklay Co. Ltd., and Takeda Pharmaceutical Company Limited. Yoshiyuki Hamamoto received consulting or speaker fees from Novo Nordisk Pharma Ltd. Takeshi Kurose received consulting or speaker fees from Sanofi K.K. Takeshi Kurose also received clinically commissioned/joint research grants from the Japan Vascular Disease Research Foundation. Yutaka Seino received consulting or speaker fees from Eli Lilly Japan K.K., Sanofi K.K., Novo Nordisk Pharma Inc., Glaxo-Smith-Kline, Taisho Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Astellas Pharma Inc., BD, Nippon Boehringer Ingelheim Co., Ltd., Johnson \& Johnson and Takeda Pharmaceutical Company Limited. Yutaka Seino also received clinically commissioned/joint research grants from Nippon Boehringer Ingelheim Co., Ltd., Eli Lilly and Company, Taisho Toyama Pharmaceutical Co. Ltd., MSD K.K., Ono Pharmaceutical Co. Ltd., Novo Nordisk Pharma Ltd., and Arklay Co. Ltd. R. The other authors declare no conflict of interest.",

year = "2018",

month = jul,

doi = "10.1111/jdi.12858",

language = "English",

volume = "9",

pages = "981--983",

journal = "Journal of Diabetes Investigation",

issn = "2040-1116",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

Usui, R, Sakuramachi, Y, Seino, Y, Murotani, K, Kuwata, H, Tatsuoka, H, Hamamoto, Y, Kurose, T, Seino, Y & Yabe, D 2018, 'Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β-cell function and the achievement of the HbA1c target 1 year after initiation', Journal of Diabetes Investigation, vol. 9, no. 4, pp. 981-983. https://doi.org/10.1111/jdi.12858

Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β-cell function and the achievement of the HbA1c target 1 year after initiation. / Usui, Ryota; Sakuramachi, Yui; Seino, Yusuke et al.
In: Journal of Diabetes Investigation, Vol. 9, No. 4, 07.2018, p. 981-983.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes

T2 - The association between remaining β-cell function and the achievement of the HbA1c target 1 year after initiation

AU - Usui, Ryota

AU - Sakuramachi, Yui

AU - Seino, Yusuke

AU - Murotani, Kenta

AU - Kuwata, Hitoshi

AU - Tatsuoka, Hisato

AU - Hamamoto, Yoshiyuki

AU - Kurose, Takeshi

AU - Seino, Yutaka

AU - Yabe, Daisuke

N1 - Funding Information: Daisuke Yabe received consulting or speaker fees from MSD K.K., Novo Nor disk Pharma Ltd., Takeda Pharmaceutical Company Limited and Taisho Toyama Pharmaceutical Co. Ltd. Daisuke Yabe also received clinically commissioned/ joint research grants from Nippon Boeh ringer Ingelheim Co., Ltd., Eli Lilly and Company, Taisho Toyama Pharmaceutical Co. Ltd., MSD K.K., Ono Pharmaceutical Co. Ltd., Novo Nordisk Pharma Ltd., Arklay Co. Ltd., and Takeda Pharmaceutical Company Limited. Yoshiyuki Hamamoto received consulting or speaker fees from Novo Nordisk Pharma Ltd. Takeshi Kurose received consulting or speaker fees from Sanofi K.K. Takeshi Kurose also received clinically commissioned/joint research grants from the Japan Vascular Disease Research Foundation. Yutaka Seino received consulting or speaker fees from Eli Lilly Japan K.K., Sanofi K.K., Novo Nordisk Pharma Inc., Glaxo-Smith-Kline, Taisho Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Astellas Pharma Inc., BD, Nippon Boehringer Ingelheim Co., Ltd., Johnson & Johnson and Takeda Pharmaceutical Company Limited. Yutaka Seino also received clinically commissioned/joint research grants from Nippon Boehringer Ingelheim Co., Ltd., Eli Lilly and Company, Taisho Toyama Pharmaceutical Co. Ltd., MSD K.K., Ono Pharmaceutical Co. Ltd., Novo Nordisk Pharma Ltd., and Arklay Co. Ltd. R. The other authors declare no conflict of interest.

PY - 2018/7

Y1 - 2018/7

UR - https://www.scopus.com/pages/publications/85050007955

UR - https://www.scopus.com/pages/publications/85050007955#tab=citedBy

U2 - 10.1111/jdi.12858

DO - 10.1111/jdi.12858

M3 - Letter

C2 - 29974670

AN - SCOPUS:85050007955

SN - 2040-1116

VL - 9

SP - 981

EP - 983

JO - Journal of Diabetes Investigation

JF - Journal of Diabetes Investigation

IS - 4

ER -

Usui R, Sakuramachi Y, Seino Y, Murotani K, Kuwata H, Tatsuoka H et al. Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β-cell function and the achievement of the HbA1c target 1 year after initiation. Journal of Diabetes Investigation. 2018 Jul;9(4):981-983. doi: 10.1111/jdi.12858

Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β-cell function and the achievement of the HbA1c target 1 year after initiation

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Cite this